Welcome to our dedicated page for Healthcare Triangle SEC filings (Ticker: HCTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Healthcare Triangle, Inc. filings document material-event reporting, shareholder voting matters, capital-structure changes, acquisition records, and governance disclosures for a healthcare information technology company. Recent 8-K filings cover the company’s Nasdaq-listed common stock, emerging growth company status, board-approved share repurchase program, and the completed reverse stock split reflected in amendments to its certificate of incorporation.
The filing record also includes proxy materials for a special stockholder meeting and material-agreement disclosures tied to subsidiary transactions. An amended 8-K provides acquired-business financial statements and pro forma financial information for Teyamé 360 S.L. and Datono Mediación S.L., connecting transaction disclosures with HCTI’s broader AI, digital health, and customer-engagement platform activity.
Healthcare Triangle, Inc. is launching an at-the-market offering of up to $20,000,000 of its common stock through Spartan Capital Securities as sales agent. Shares may be sold from time to time on Nasdaq under the symbol HCTI, with Spartan earning a 3% commission on gross sales.
The company plans to use any net proceeds for general corporate purposes, including potential acquisitions and working capital. An illustrative scenario assumes selling 9,569,377 shares at $2.09 per share, which would raise $20 million and increase as-adjusted net tangible book value to $1.48 per share, while creating $0.61 per-share dilution for new investors.
Recent actions include a 1-for-249 reverse stock split that reduced outstanding shares to 5,831,816, a warrant inducement that generated approximately $2.85 million in gross proceeds, and a $5.7 million asset and equity acquisition from Niyama Healthcare to expand mental health and hospital information systems capabilities.
Healthcare Triangle, Inc. (HCTI) has called a virtual-only special meeting of stockholders on November 28, 2025 to vote on a single key item. Stockholders are being asked to approve, for purposes of Nasdaq Listing Rule 5635(d), future issuances of the Company’s securities in an aggregate amount of up to $70 million during the period from November 14, 2025 until February 28, 2026, as long as each issuance meets specified Nasdaq parameters.
Nasdaq Rule 5635(d) generally requires stockholder approval when a company issues 20% or more of its common stock (or voting power) in certain non‑public transactions at prices below a defined minimum. Approval of this proposal would satisfy that requirement for qualifying transactions completed within the stated period. The Company notes that any such future issuances under these parameters would have a dilutive effect on existing stockholders’ ownership and voting power over time. Only stockholders of record as of November 12, 2025 are entitled to vote, and the Board unanimously recommends voting “FOR” the proposal.
Healthcare Triangle, Inc. reported Q3 results with net revenue of $3,489 (up 45% year over year) and a net loss of $1,906. For the nine months, revenue was $10,752 (up 13%), with a net loss of $4,973. Segment mix shifted toward Software Services, while Managed Services declined.
Liquidity and the balance sheet changed markedly. Cash and cash equivalents were $1,629 as of September 30, 2025. Net cash used in operating activities was $9,689, offset by $12,587 of net financing cash inflows primarily from equity issuance. Total assets rose to $13,838 from $1,961 at year‑end, reflecting the June 16 acquisition of Niyama Healthcare/Ezovion (purchase price $5,700, including cash, 1,388,041 restricted shares valued at $3,000, and up to $1,200 earn‑out). Stockholders’ equity improved to $8,726 from a deficit.
The company effected a 1‑for‑249 reverse stock split on August 1, 2025. Short‑term borrowing under the Seacoast facility was $1,530, and convertible notes were eliminated through conversion and repayment. As of November 13, 2025, 7,261,344 common shares were outstanding.
Healthcare Triangle, Inc. reported results of its November 7, 2025 annual meeting. Shareholders elected four directors for one-year terms and ratified SRCO Professional Corporation as independent auditor for 2025.
Participation was strong: 21,423,722 shares (approximately 82.80% of 25,873,304 entitled shares) were represented, including common stock and Series A Super Voting Preferred Stock.
Director votes: Sujatha Ramesh For 20,253,344, Withheld 7,524; Dave Rosa For 20,171,021, Withheld 89,847; Jainal Bhuiyan For 20,244,585, Withheld 16,283; Ron McClurg For 20,250,055, Withheld 10,813. Each director vote recorded 1,162,854 broker non-votes.
Auditor ratification: For 21,275,588, Against 57,036, Abstain 91,098, with 0 broker non-votes.
Healthcare Triangle, Inc. (HCTI) called a virtual‑only special meeting for December 16, 2025 to seek stockholder approval, for purposes of Nasdaq Listing Rule 5635(d), of potential issuances of securities completed from the meeting date for three months in an aggregate amount up to $[50] million, if each issuance meets stated Nasdaq Parameters.
The company lists parameters and a latest closing date no later than February [●], 2026, and states the purpose is to provide additional working capital. The filing notes that any such issuances will dilute existing stockholders over time, including their voting power. Only stockholders of record as of November [●], 2025 may vote, and the meeting will be accessible via live webcast only.
Healthcare Triangle, Inc. filed an S-3 registering the resale of up to 1,458,118 shares of common stock issuable upon exercise of previously issued warrants, including 1,429,528 shares tied to new Inducement Warrants and 28,590 shares tied to Inducement Advisor Warrants. The company is not selling shares in this registration and will receive no proceeds from any resale; it may receive cash only if warrants are exercised.
The Inducement Warrants carry a $3.00 per-share exercise price and become exercisable after stockholder approval for issuances above 19.99% of outstanding common stock, with a five-year term and a 4.99% (or 9.99% at holder election) beneficial ownership cap. The filing allows selling stockholders to use customary methods to dispose of shares. Examples of registered amounts per holder include Robert Forster 286,862 and Bigger Capital Fund, LP 191,241. The company states warrant exercise proceeds, if any, would be used for working capital and general corporate purposes.
Healthcare Triangle (HCTI) called its 2025 Annual Meeting for November 7, 2025 at 10:00 a.m. Pacific Time, to be held virtually. Stockholders will vote to elect four directors and to ratify SRCO Professional Corporation as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The Board unanimously recommends voting FOR all nominees and FOR auditor ratification.
Only stockholders of record at the close of business on September 29, 2025 may vote. Registration to attend is required by November 5, 2025 at 11:59 p.m. Eastern Time. Nominees are Dave Rosa, Sujatha Ramesh, Ronald McClurg, and Jainal Bhuiyan.
SRCO has served as auditor since April 2025; prior reports by M&K CPAS, PLLC contained no adverse opinions or modifications. As context, Suresh Venkatachari holds Series A Super Voting Preferred Shares representing 77.11% of voting power as of October 15, 2025. Shares outstanding were 5,873,304 common and 20,000 Series A Super Voting Preferred as of October 15, 2025.
Healthcare Triangle, Inc. (HCTI) reported that a holder of approximately 81.82% of its voting power approved, by written consent, the issuance of 1,388,041 restricted common shares to Niyama Healthcare, Inc. as partial consideration for an acquisition. The deal also includes $1.5 million in cash (with $1.2 million paid at closing and $300,000 payable later) and up to $1.2 million in earn-out payments tied to first‑year performance targets to be agreed within 90 days of closing.
The shares are being issued under Nasdaq Listing Rule 5635(a)(2). The action becomes effective 20 calendar days after mailing of the information statement. Shares outstanding were 5,831,829 as of September 19, 2025; this is a baseline figure, not the amount being issued.
HCTI acquired the seller’s cloud and technology domain assets and 100% of Ezovion Solutions Private Limited, a hospital information systems SaaS provider in Chennai, India. No proxy is being solicited, and no further shareholder action is required.
Healthcare Triangle, Inc. entered into a warrant inducement agreement under which certain existing warrant holders agreed to exercise warrants for cash to buy up to 1,429,528 shares of common stock at $2.00 per share. The exercises, completed on October 2, 3 and 8, 2025, generated aggregate gross proceeds of approximately $2.85 million before fees and expenses, which the company expects to use for working capital and general corporate purposes.
In return, the company issued new unregistered warrants for up to 1,429,528 additional shares at an exercise price of $3.00 per share, with a five-year term and exercisability beginning after required stockholder approval. A financial advisor received a 6.0% cash fee on gross proceeds, expense reimbursement up to $20,000, advisor warrants equal to about 2.0% of the new warrant shares at $3.00 per share, and a six-month right of first refusal on future offerings. The new warrants include ownership caps of 4.99% or 9.99% and permit cashless exercise if a registration for the new warrant shares is not effective after six months.
Healthcare Triangle, Inc. is circulating a preliminary proxy statement for a virtual annual meeting that includes three explicit actions: elect four directors to serve until the 2026 annual meeting, ratify the appointment of SRCO Professional Corporation, Chartered Professional Accountants as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and transact any other properly presented business. The materials describe voting mechanics for record holders and beneficial holders, note that a quorum requires a majority of outstanding voting stock, and state there are 20,000 shares of Series A Super Voting Preferred Stock outstanding with 1,000 votes per share; the number of common shares outstanding is presented as a placeholder and not specified. The company will pay proxy-solicitation costs and reimburse brokers for forwarding materials. Healthcare Triangle discloses it is an "emerging growth company" and summarizes committee responsibilities, director names and ages (Dave Rosa, Sujatha Ramesh, Ronald McClurg, Jainal Bhuiyan). Several ownership and disclosure fields in the filing appear as placeholders or truncated.